Publication
Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-pentetreotide scintigraphy
| dc.contributor.author | Moreira, AP | |
| dc.contributor.author | Duarte, LH | |
| dc.contributor.author | Vieira, F | |
| dc.contributor.author | João, F | |
| dc.contributor.author | Pedroso de Lima, J | |
| dc.date.accessioned | 2011-01-27T13:03:19Z | |
| dc.date.available | 2011-01-27T13:03:19Z | |
| dc.date.issued | 2005 | |
| dc.description.abstract | OBJECTIVE: The purpose of this study was to evaluate the impact and clinical value of anatomical-functional image fusion in the study interpretation and clinical management of patients with neuroendocrine tumours (NET) using somatostatin receptor scintigraphy (SRS) and combined transmission and emission tomography -- single-photon emission tomography/CT (SPET/CT). MATERIAL AND METHODS: Twelve patients (8 female and 4 male; age range 32-74 y, mean 56 y) with proven or clinically suspected NET were studied with routine planar SRS and SPET/CT at 2 and 24 hours after injection of 111-222 MBq 111In-Pentetreotide. Seven patients came for staging/follow-up and 5 patients for primary tumour localization with staging. Analysis of fused images (SPET/CT) was done on a patient basis, with separated evaluation of SPET, low-dose CT images and fusion images. The gold standard for presence or absence of malignancy was pathology or clinical and imaging follow-up data. RESULTS: SRS was negative in 6 patients and positive in 6. SPET/CT provided no additional information in 6 patients, including all 6 negative studies. SPET/CT improved localization of SPET detected lesions in 6 positive studies. It defined the extent of the disease and showed bone involvement in 3 of the 6 positive studies. SPET/CT affected the diagnostic interpretation in 6 patients (50 %) and induced changes of management in 3 (25 %). CONCLUSION: The results of this study indicate that combined anatomical-functional imaging with SPET/CT significantly improves tumour localization and characterization, contributing to a better therapeutic management of patients with NET. | por |
| dc.identifier.citation | Rev Esp Med Nucl. 2005 Jan-Feb;24(1):14-8. | por |
| dc.identifier.uri | http://hdl.handle.net/10400.4/980 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.subject | Tumores Neuroendócrinos | por |
| dc.subject | Tomografia de Emissão de Positrões | por |
| dc.subject | Tomografia Computorizada | por |
| dc.subject | Somatostatina | por |
| dc.title | Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-pentetreotide scintigraphy | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |